Sermorelin

The Sermorelin evidence base cited here is 7 sources — 3 clinical, 2 review, 1 regulatory. Its strongest evidence is human — 3 clinical studies, most recently 1997 ("Endocrine and Metabolic Effects of Long-Term Administration of GHRH(1-29…"). Regulatory status: Previously FDA-approved.

Sermorelin and CJC-1295 are the two most-discussed GHRH analogs, so a direct comparison is useful. Both hit the GHRH receptor; the difference is half-life and the resulting GH-release pattern.

The short half-life that looks like a weakness is arguably the point: sermorelin's brief pulse mimics the body's own secretory rhythm and keeps somatostatin feedback intact, whereas DAC-CJC-1295's days-long elevation departs from that natural pulsatility. For the synergistic GH boost, GHRH analogs are usually paired with a GHRP (ghrelin-receptor agonist), not with each other — see Stacking.

• Sermorelin (GRF 1-29 / GHRH 1-29) is a synthetic 29-amino-acid peptide identical to the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH), used to stimulate the body's own GH production.
• It works upstream of the pituitary — activating the same GHRHR that endogenous GHRH does — so GH release stays pulsatile and subject to somatostatin feedback, preserving the hypothalamic-pituitary axis rather than overriding it (the key contrast with exogenous GH).
• It was genuinely FDA-approved (Geref) for pediatric GH deficiency and diagnostic use, then voluntarily withdrawn in 2008 for commercial reasons — the FDA confirmed in 2013 it was NOT withdrawn for safety/efficacy, which is what makes it legally compoundable today under Section 503A.

Sermorelin is a synthetic peptide made of the first 29 amino acids of human GHRH — the shortest fully active fragment of the native hormone. Rather than supplying growth hormone directly, it prompts the pituitary to release the body's own GH, working through the same receptor and the same feedback controls as natural GHRH.

It is unusual among anti-aging peptides in having a real regulatory pedigree: it was FDA-approved as Geref for pediatric GH deficiency and as a diagnostic agent before being withdrawn in 2008 for purely commercial reasons. That history, plus a 2013 FDA confirmation that the withdrawal was not safety-related, is why licensed compounding pharmacies can legally prepare it by prescription today.

The pediatric GH-deficiency data is strong; the adult anti-aging applications rest on smaller, shorter studies. Everything below is research and clinical context synthesized from the published literature — not medical guidance, and not a self-administration protocol. Sermorelin is a prescription medication that should be used under a qualified provider's supervision.

Sermorelin (also GRF 1-29 or GHRH 1-29) is the biologically active N-terminal fragment of the 44-amino-acid human GHRH molecule. Early-1980s research established that residues 1–29 retain full activity at the pituitary GHRH receptor, making sermorelin the shortest fully functional GHRH fragment. Its molecular weight is ≈ 3,358 Da.

The FDA approved sermorelin injection for diagnostic use under NDA 19-863 in December 1990, then Geref (0.5 mg and 1.0 mg vials) under NDA 20-443 in September 1997 for idiopathic GH deficiency in children with growth failure. EMD Serono, the sole manufacturer, voluntarily ceased production in 2008 as recombinant human GH (rhGH) took over the pediatric GHD market and made Geref commercially unviable; the FDA formally withdrew the NDA in June 2009 but confirmed in a 2013 Federal Register notice that the withdrawal was not for reasons of safety or effectiveness.

What sets sermorelin apart from other GHRH analogs is its close structural identity to native GHRH. Unlike CJC-1295 — which adds amino-acid substitutions and (in its DAC form) an albumin-binding moiety to extend half-life to days — sermorelin's half-life is only ~11–12 minutes, producing brief, physiological GH pulses. Compared with tesamorelin (a 44-aa modified GHRH analog FDA-approved for HIV-associated lipodystrophy), sermorelin is smaller and less protease-resistant but has a longer clinical track record across more indications.

Sermorelin is a prescription medication; dosing is individualized by a licensed provider based on age, weight, baseline IGF-1, and goals. The ranges below come from the clinical literature and compounding-pharmacy prescribing conventions, included for research context only — not as instructions for self-administration.

• Standard anti-aging/wellness range: ~200–300 mcg subcutaneously at bedtime, 5–7 nights/week.
• Conservative start: ~100–200 mcg at bedtime for the first 2–4 weeks, titrated by tolerance and response.
• Higher-end clinical dosing: ~300–500 mcg at bedtime, typically reserved for documented low IGF-1 or poor initial response.
• Pediatric (historical FDA-approved Geref labeling): 30 mcg/kg subcutaneously at bedtime.

Most protocols use 5-nights-on/2-off to balance benefit with rest; some start nightly for 3–6 months first. Cycling isn't universally required given the axis-preserving mechanism, but periodic IGF-1 monitoring (every 3–6 months) is standard. Tolerance to GHRH-receptor activation appears to develop slowly, if at all — unlike ghrelin-receptor secretagogues.

Sermorelin is given by subcutaneous injection (abdomen, thigh, or posterior upper arm) under a provider's direction. The timing rationale is the pharmacologically important part: the largest physiological GH pulse occurs during early slow-wave sleep, when somatostatin tone is lowest, so dosing 15–30 minutes before bed synchronizes GHRH-receptor stimulation with that natural secretory window. Daytime dosing, when somatostatin is high, substantially blunts the GH response.

Administration on an empty stomach (at least ~90 minutes after the last meal) is generally recommended, since elevated glucose and insulin attenuate the GH response. Injection sites are rotated to avoid local irritation or lipodystrophy.

Responses vary with age, baseline GH/IGF-1, body composition, diet, and exercise. The following reflects patterns from clinical studies and prescriber experience.

Maximum benefit is generally seen at the 3–6-month mark with consistent use; providers typically reassess IGF-1 and clinical response at ~3-month intervals.

Pairing a GHRH analog like sermorelin with a GH-releasing peptide (GHRP, a ghrelin-receptor agonist) produces a synergistic effect exceeding either alone, because the two act on different receptor pathways that converge on the somatotroph. Research context, not protocol advice.

• Sermorelin + Ipamorelin — the most widely prescribed combination: sermorelin gives the GHRH signal while ipamorelin activates the ghrelin/GHS-R1a pathway, a dual stimulus. Ipamorelin is favored because it doesn't meaningfully raise cortisol, prolactin, or appetite. Common pairing: ~200–300 mcg of each at bedtime.
• Sermorelin + GHRP-6 — older, robust GH release (co-administration of GHRH with the related GHRP-2 produced a reported ~54-fold GH increase vs baseline), but GHRP-6 is less selective — it raises cortisol/prolactin and stimulates appetite via the ghrelin receptor.
• Sermorelin + CJC-1295 (no DAC) — both GHRH analogs on the same pathway, so this lacks the GHRH+GHRP synergy; some protocols use it for extra receptor occupancy with a slightly different PK, but it's less common and less evidence-based.

Sermorelin is supplied as a lyophilized powder (commonly 2–5 mg vials) requiring reconstitution. The following reflects general handling for a compounded peptide.

• Bring vial and bacteriostatic water to room temperature; wipe stoppers with alcohol; add water slowly down the glass wall (never spray onto the powder) and swirl gently until clear and colorless — never shake (shaking can denature the peptide).
• Common ratio: 3 mg + 3 mL bacteriostatic water = 1 mg/mL (a 300 mcg dose = 0.3 mL / 30 units on an insulin syringe).
• Unreconstituted powder: stable at room temperature; refrigerate at 2–8°C for long-term storage (12+ months).
• Reconstituted solution: refrigerate at 2–8°C, use within ~4–6 weeks; never freeze (ice crystals damage the peptide); discard after >72 h at room temperature; protect from light and heat.
• Use bacteriostatic water (0.9% benzyl alcohol), not sterile water, for multi-dose vials to prevent contamination.

Sermorelin has a well-established safety profile from its years as an FDA-approved medication. The following come from clinical trials and post-marketing experience.

Precautions/contraindications: active malignancy (GH/IGF-1 may promote tumor growth); untreated hypothyroidism (impairs GH response — correct first); concomitant glucocorticoids (attenuate effect); obesity (blunted GH response). As a hormone-modulating therapy, use belongs under provider supervision with biomarker monitoring.

Sermorelin's regulatory history is unique among anti-aging peptides: it was once a fully FDA-approved medication with a completed NDA, clinical-trial data, and an established safety profile.

• 1988: FDA orphan-drug designation for idiopathic/organic GH deficiency in children.
• Dec 1990: NDA 19-863 approved (sermorelin injection, diagnostic use).
• Sep 1997: NDA 20-443 approved (Geref, pediatric GHD treatment).
• Dec 2008: EMD Serono notifies FDA of voluntary discontinuation (commercial reasons).
• Jun 2009: FDA formally withdraws NDA approval.
• Mar 2013: FDA Federal Register determination confirms Geref was NOT withdrawn for reasons of safety or effectiveness.

The 2013 determination is what enables legal compounding: under Section 503A, licensed pharmacies may prepare sermorelin per-prescription for individual patients, and 503B outsourcing facilities may compound it under FDA oversight (pharmaceutical-grade API with a valid COA). Sermorelin is not a controlled substance, but it is a prescription medication — it cannot be sold OTC, as a supplement, or marketed for human use without a valid prescription.

Sermorelin is explicitly prohibited by WADA under Section S2.2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) — specifically S2.2.4 as a GHRH analog, alongside CJC-1295 and tesamorelin. The ban applies at all times, in- and out-of-competition. All GH secretagogues — GHS-R agonists (ipamorelin, ibutamoren) and GHRH analogs (sermorelin, CJC-1295, tesamorelin) — are banned for their capacity to raise GH and IGF-1. A Therapeutic Use Exemption is theoretically possible but very difficult for S2 substances; tested athletes should treat sermorelin as a disqualifying violation.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.